Biogen Accounts Payable vs Net Income Analysis

BIIB Stock  USD 215.63  0.71  0.33%   
Biogen financial indicator trend analysis is way more than just evaluating Biogen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biogen Inc is a good investment. Please check the relationship between Biogen Accounts Payable and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

Accounts Payable vs Net Income

Accounts Payable vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biogen Inc Accounts Payable account and Net Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Biogen's Accounts Payable and Net Income is 0.47. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Income in the same time period over historical financial statements of Biogen Inc, assuming nothing else is changed. The correlation between historical values of Biogen's Accounts Payable and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Biogen Inc are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Accounts Payable i.e., Biogen's Accounts Payable and Net Income go up and down completely randomly.

Correlation Coefficient

0.47
Relationship DirectionPositive 
Relationship StrengthWeak

Accounts Payable

An accounting item on the balance sheet that represents Biogen obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Biogen Inc are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Biogen Inc financial statement analysis. It represents the amount of money remaining after all of Biogen Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from Biogen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biogen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
At present, Biogen's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 17.67, whereas Tax Provision is forecasted to decline to about 128.5 M.
 2021 2022 2023 2024 (projected)
Gross Profit8.9B7.9B7.3B3.9B
Total Revenue11.0B10.2B9.8B10.3B

Biogen fundamental ratios Correlations

0.920.670.950.940.960.850.990.630.99-0.570.610.97-0.740.940.56-0.820.960.860.930.590.89-0.80.3-0.80.39
0.920.630.860.760.890.960.90.580.9-0.720.590.85-0.620.980.54-0.920.970.80.870.450.83-0.630.33-0.630.29
0.670.630.780.530.640.460.630.790.58-0.430.880.59-0.670.690.45-0.640.730.240.79-0.10.73-0.560.74-0.560.44
0.950.860.780.850.920.750.910.720.92-0.530.670.88-0.740.890.45-0.790.940.750.90.430.94-0.740.34-0.740.52
0.940.760.530.850.890.680.940.560.93-0.370.520.95-0.730.780.54-0.630.820.860.870.70.79-0.850.18-0.850.29
0.960.890.640.920.890.820.920.590.96-0.50.540.95-0.780.920.56-0.750.940.880.870.50.95-0.780.21-0.780.44
0.850.960.460.750.680.820.830.330.86-0.70.380.78-0.50.940.48-0.860.910.810.730.540.71-0.560.22-0.560.22
0.990.90.630.910.940.920.830.630.97-0.620.60.97-0.660.920.51-0.850.940.850.930.610.83-0.730.28-0.730.33
0.630.580.790.720.560.590.330.630.51-0.410.90.59-0.640.590.42-0.60.640.30.83-0.070.72-0.470.52-0.470.34
0.990.90.580.920.930.960.860.970.51-0.550.490.96-0.690.930.52-0.780.950.910.860.670.86-0.780.18-0.780.4
-0.57-0.72-0.43-0.53-0.37-0.5-0.7-0.62-0.41-0.55-0.38-0.520.14-0.72-0.20.87-0.68-0.46-0.55-0.26-0.470.06-0.20.06-0.18
0.610.590.880.670.520.540.380.60.90.49-0.380.53-0.60.610.53-0.60.640.180.84-0.140.62-0.550.83-0.550.37
0.970.850.590.880.950.950.780.970.590.96-0.520.53-0.710.880.52-0.770.90.880.890.60.85-0.750.18-0.750.32
-0.74-0.62-0.67-0.74-0.73-0.78-0.5-0.66-0.64-0.690.14-0.6-0.71-0.64-0.570.42-0.68-0.56-0.75-0.26-0.80.85-0.360.85-0.28
0.940.980.690.890.780.920.940.920.590.93-0.720.610.88-0.640.55-0.920.990.790.880.430.85-0.650.37-0.650.39
0.560.540.450.450.540.560.480.510.420.52-0.20.530.52-0.570.55-0.330.530.430.60.190.51-0.650.43-0.650.05
-0.82-0.92-0.64-0.79-0.63-0.75-0.86-0.85-0.6-0.780.87-0.6-0.770.42-0.92-0.33-0.9-0.64-0.81-0.32-0.710.37-0.370.37-0.33
0.960.970.730.940.820.940.910.940.640.95-0.680.640.9-0.680.990.53-0.90.790.910.440.89-0.690.37-0.690.44
0.860.80.240.750.860.880.810.850.30.91-0.460.180.88-0.560.790.43-0.640.790.670.780.76-0.65-0.17-0.650.25
0.930.870.790.90.870.870.730.930.830.86-0.550.840.89-0.750.880.6-0.810.910.670.350.85-0.760.53-0.760.33
0.590.45-0.10.430.70.50.540.61-0.070.67-0.26-0.140.6-0.260.430.19-0.320.440.780.350.32-0.53-0.35-0.53-0.08
0.890.830.730.940.790.950.710.830.720.86-0.470.620.85-0.80.850.51-0.710.890.760.850.32-0.710.25-0.710.5
-0.8-0.63-0.56-0.74-0.85-0.78-0.56-0.73-0.47-0.780.06-0.55-0.750.85-0.65-0.650.37-0.69-0.65-0.76-0.53-0.71-0.361.0-0.22
0.30.330.740.340.180.210.220.280.520.18-0.20.830.18-0.360.370.43-0.370.37-0.170.53-0.350.25-0.36-0.360.29
-0.8-0.63-0.56-0.74-0.85-0.78-0.56-0.73-0.47-0.780.06-0.55-0.750.85-0.65-0.650.37-0.69-0.65-0.76-0.53-0.711.0-0.36-0.22
0.390.290.440.520.290.440.220.330.340.4-0.180.370.32-0.280.390.05-0.330.440.250.33-0.080.5-0.220.29-0.22
Click cells to compare fundamentals

Biogen Account Relationship Matchups

Biogen fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets27.2B24.6B23.9B24.6B26.8B28.2B
Short Long Term Debt Total6.4B7.8B7.6B6.6B7.3B7.7B
Other Current Liab3.4B3.3B3.3B2.8B838.4M969.8M
Total Current Liabilities4.9B3.7B4.3B3.3B3.4B3.6B
Total Stockholder Equity13.3B10.7B11.0B13.4B14.8B15.5B
Property Plant And Equipment Net3.7B3.8B3.8B3.7B3.7B3.9B
Net Debt3.5B6.5B5.3B3.2B6.3B6.6B
Retained Earnings16.5B14.0B13.9B16.5B17.6B18.5B
Cash2.9B1.3B2.3B3.4B1.0B723.1M
Non Current Assets Total18.9B17.7B16.0B14.8B20.0B21.0B
Non Currrent Assets Other(3.2B)(1.4B)1.9B1.5B284.3M270.1M
Cash And Short Term Investments4.5B2.6B3.8B4.9B1.0B1.5B
Net Receivables1.9B1.9B1.5B2.1B2.1B2.2B
Common Stock Shares Outstanding187.4M161.3M149.6M146M145.6M283.0M
Liabilities And Stockholders Equity27.2B24.6B23.9B24.6B26.8B28.2B
Non Current Liabilities Total9.0B10.2B8.6B7.9B8.6B9.0B
Other Current Assets1.2B1.3B1.2B1.4B1.2B1.2B
Other Stockholder Equity(3.0B)(3.0B)(2.8B)(2.9B)(2.7B)(2.5B)
Total Liab13.9B13.9B12.9B11.2B12.0B12.6B
Property Plant And Equipment Gross3.7B3.8B3.8B3.7B6.1B6.4B
Total Current Assets8.4B6.9B7.9B9.8B6.9B7.2B
Accumulated Other Comprehensive Income(135.2M)(299M)(106.7M)(164.9M)(153.7M)(146.0M)
Intangible Assets3.5B3.1B2.2B1.9B8.4B8.8B
Accounts Payable530.8M454.9M589.2M491.5M403.3M423.5M
Short Term Investments2.3B1.6B1.3B1.5B1.5B0.0
Inventory804.2M1.1B1.4B1.3B2.5B2.7B
Other Liab4.2B2.4B2.0B1.3B1.5B969.6M
Other Assets3.2B4.2B3.4B1.7B1.9B2.0B
Long Term Debt4.5B7.4B6.3B6.3B6.8B7.1B
Property Plant Equipment3.2B3.4B3.4B3.3B3.8B2.1B
Good Will5.8B5.8B5.8B5.7B6.2B3.2B
Net Tangible Assets4.1B1.9B2.9B5.8B6.7B4.1B
Noncontrolling Interest In Consolidated Entity(4.1M)(14.2M)63.5M(9.5M)(8.6M)(8.1M)
Retained Earnings Total Equity16.5B14.0B13.9B16.5B18.9B11.5B

Pair Trading with Biogen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biogen Stock

  0.8MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Biogen Stock

  0.92EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.9DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.81MDWD Mediwound Financial Report 4th of June 2024 PairCorr
  0.81MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.77TCRX Tscan Therapeutics Financial Report 8th of May 2024 PairCorr
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Biogen Stock analysis

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.55)
Earnings Share
7.96
Revenue Per Share
67.972
Quarterly Revenue Growth
(0.06)
Return On Assets
0.0458
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.